The Johnson & Johnson vaccine clinical trial comes to Sacramento California as Benchmark Research’s Van Johnson, vice president of business development and global alliances, explains the importance of minority participation in COVID-19 vaccine trials. Thus far, while the COVID-19 vaccine studies have made promising inroads into what are typically underrepresented populations in research, the status quo isn’t sufficient. Key for regulatory approval, minority participation ensures vaccine makers, investigational sites, and regulators have a good understanding on how well a particular drug or vaccine may work in a specific cohort or population. In vaccine studies that don’t include sufficient numbers of people from a particularly large demographic group, challenges could arise with real world use.
TrialSite reported on Benchmark Research’s efforts to recruit participants form the Moderna study, including at their site here in Sacramento, California.
Minorities Advancing Clinical Research (MACRO)
Recently reported by local media KCRA, the nationally focused trial site organization has created the MACRO program with a mission to educate people in minority communities ...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).